Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...

Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...

Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic mainstream.

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

CagriSema, which is a combination of cagrilintide 2.4-milligram and semaglutide 2.4-mg doses, is being developed so people have a better choice for a weight-loss drug when the patents on Ozempic and ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

As earnings season begins, filings to the SEC point to uncertainty from the current administration as potential trouble for ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...